Transmission blocking vaccine study in Plasmodium vivax

Information

  • Research Project
  • 9067313
  • ApplicationId
    9067313
  • Core Project Number
    R01AI099611
  • Full Project Number
    5R01AI099611-05
  • Serial Number
    099611
  • FOA Number
    PAR-11-145
  • Sub Project Id
  • Project Start Date
    6/20/2012 - 11 years ago
  • Project End Date
    5/31/2017 - 7 years ago
  • Program Officer Name
    MO, ANNIE X. Y.
  • Budget Start Date
    6/1/2016 - 8 years ago
  • Budget End Date
    5/31/2017 - 7 years ago
  • Fiscal Year
    2016
  • Support Year
    05
  • Suffix
  • Award Notice Date
    5/13/2016 - 8 years ago
Organizations

Transmission blocking vaccine study in Plasmodium vivax

DESCRIPTION (provided by applicant): With improved financial and technical supports, many malaria endemic nations are once again considering a goal of malaria elimination. However, this ambitious goal is met with tremendous technical difficulties especially in regions where Plasmodium vivax is prevalent. Interruption of malaria transmission worldwide has been recognized as one of the greatest challenges in malaria elimination. Vaccines that interrupt malaria transmission are ideally suited to this task. However, the progress in development of transmission blocking vaccines (TBVs) has been very slow. To date, we only have a few TBV immunogens with compelling evidence of transmission blocking activities. For P. vivax, TBV studies lag even behind and only two post-fertilization antigens Pvs25 and Pvs28 have been studied. Therefore, this application targets the serious deficiency of knowledge about pre-fertilization stage antigens in the neglected P. vivax parasite using systematic approaches including antigen discovery in rodent malaria parasites, validation of transmission blocking activities in P. vivax, and development of novel vaccine delivery tools. We aim to 1) identify new sexual stage antigens and evaluate their transmission blocking potentials in the rodent malaria parasite P. berghei; 2) validate known pre-fertilization TBV candidates and newly identified candidates using fresh P. vivax clinical isolates; and 3) improve transmission blocking activities of antigens by expressing the antigens in a baculovirus surface display system and by using a TBV combination strategy targeting both pre- and post-fertilization antigens simultaneously. Results from these comprehensive studies will contribute to increased knowledge about TBV development, which is urgently needed for the ultimate elimination of vivax malaria.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R01
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
    121450
  • Indirect Cost Amount
    9716
  • Total Cost
    131166
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:131166\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CHINA MEDICAL UNIVERSITY
  • Organization Department
  • Organization DUNS
    529786253
  • Organization City
    SHENYANG
  • Organization State
  • Organization Country
    CHINA
  • Organization Zip Code
    110122
  • Organization District
    CHINA